Cargando…

Flexible Risk Evidence Combination Rules in Breast Cancer Precision Therapy

Evidence theory by Dempster-Shafer for determination of hormone receptor status in breast cancer samples was introduced in our previous paper. One major topic pointed out here is the link between pieces of evidence found from different origins. In this paper the challenge of selecting appropriate wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenn, Michael, Karch, Rudolf, Singer, Christian F., Dorffner, Georg, Schreiner, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865003/
https://www.ncbi.nlm.nih.gov/pubmed/36675780
http://dx.doi.org/10.3390/jpm13010119
_version_ 1784875727710060544
author Kenn, Michael
Karch, Rudolf
Singer, Christian F.
Dorffner, Georg
Schreiner, Wolfgang
author_facet Kenn, Michael
Karch, Rudolf
Singer, Christian F.
Dorffner, Georg
Schreiner, Wolfgang
author_sort Kenn, Michael
collection PubMed
description Evidence theory by Dempster-Shafer for determination of hormone receptor status in breast cancer samples was introduced in our previous paper. One major topic pointed out here is the link between pieces of evidence found from different origins. In this paper the challenge of selecting appropriate ways of fusing evidence, depending on the type and quality of data involved is addressed. A parameterized family of evidence combination rules, covering the full range of potential needs, from emphasizing discrepancies in the measurements to aspiring accordance, is covered. The consequences for real patient samples are shown by modeling different decision strategies.
format Online
Article
Text
id pubmed-9865003
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98650032023-01-22 Flexible Risk Evidence Combination Rules in Breast Cancer Precision Therapy Kenn, Michael Karch, Rudolf Singer, Christian F. Dorffner, Georg Schreiner, Wolfgang J Pers Med Article Evidence theory by Dempster-Shafer for determination of hormone receptor status in breast cancer samples was introduced in our previous paper. One major topic pointed out here is the link between pieces of evidence found from different origins. In this paper the challenge of selecting appropriate ways of fusing evidence, depending on the type and quality of data involved is addressed. A parameterized family of evidence combination rules, covering the full range of potential needs, from emphasizing discrepancies in the measurements to aspiring accordance, is covered. The consequences for real patient samples are shown by modeling different decision strategies. MDPI 2023-01-05 /pmc/articles/PMC9865003/ /pubmed/36675780 http://dx.doi.org/10.3390/jpm13010119 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kenn, Michael
Karch, Rudolf
Singer, Christian F.
Dorffner, Georg
Schreiner, Wolfgang
Flexible Risk Evidence Combination Rules in Breast Cancer Precision Therapy
title Flexible Risk Evidence Combination Rules in Breast Cancer Precision Therapy
title_full Flexible Risk Evidence Combination Rules in Breast Cancer Precision Therapy
title_fullStr Flexible Risk Evidence Combination Rules in Breast Cancer Precision Therapy
title_full_unstemmed Flexible Risk Evidence Combination Rules in Breast Cancer Precision Therapy
title_short Flexible Risk Evidence Combination Rules in Breast Cancer Precision Therapy
title_sort flexible risk evidence combination rules in breast cancer precision therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865003/
https://www.ncbi.nlm.nih.gov/pubmed/36675780
http://dx.doi.org/10.3390/jpm13010119
work_keys_str_mv AT kennmichael flexibleriskevidencecombinationrulesinbreastcancerprecisiontherapy
AT karchrudolf flexibleriskevidencecombinationrulesinbreastcancerprecisiontherapy
AT singerchristianf flexibleriskevidencecombinationrulesinbreastcancerprecisiontherapy
AT dorffnergeorg flexibleriskevidencecombinationrulesinbreastcancerprecisiontherapy
AT schreinerwolfgang flexibleriskevidencecombinationrulesinbreastcancerprecisiontherapy